Literature DB >> 9831403

Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis.

S C Lindgren1, L M Flood, A F Kilander, R Löfberg, T B Persson, R I Sjödahl.   

Abstract

OBJECTIVE: To analyse the ability of simple clinical and biochemical parameters to predict glucocorticosteroid (GCS) treatment failure in patients with acute attacks of ulcerative colitis. DESIGN/
METHODS: Retrospective analysis of clinical and biochemical data.
SETTING: Four Swedish university hospitals. PATIENTS: Ninety seven patients with acute attacks of ulcerative colitis severe enough to warrant treatment with intravenous GCS, hospitalized during the years 1988-93. MAIN OUTCOME MEASURE: Colectomy within the first 30 days after hospitalization, defined as 'clinical steroid resistance'.
RESULTS: Thirty days after admission, 39 patients (40%) were in complete clinical and endoscopic remission while 33 (34%) had undergone colectomy. During follow-up for 24 months, four patients among the 39 initially in remission underwent colectomy. Among the 25 patients (26%) not attaining remission after 30 days, an additional nine patients subsequently required colectomy. Steroid resistance was associated with duration of disease (2.7 vs 8.1 years, P=0.0037) and steroid treatment before hospitalization (70 vs 42%, P=0.010). In particular, elevation of body temperature (37.4 vs 36.9 degrees C, P=0.012), persistence of diarrhoea (6.8 vs 3.6 bowel movements/day, P<0.0001) and passage of blood (83 vs 42%, P=0.0003) as well as CRP elevation (36.3 vs 18.0 mg/l, P=0.007) on day 3 after treatment initiation were identified as predictors of a poor response. CRP > or = 25 mg/l and > 4 bowel movements/day on day 3 of hospitalization independently predicted a high risk for colectomy within 30 days.
CONCLUSIONS: Sustained elevation of body temperature, persistent bloody diarrhoea and continued CRP elevation on day 3 of intravenous GCS treatment strongly predict clinical steroid resistance in acute attacks of ulcerative colitis. In the group of poor or non-responders, colectomy or more aggressive medical treatment should be considered at an early stage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9831403     DOI: 10.1097/00042737-199810000-00003

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  41 in total

Review 1.  Surgical treatment of ulcerative colitis in the biologic therapy era.

Authors:  Alberto Biondi; Marco Zoccali; Stefano Costa; Albert Troci; Ettore Contessini-Avesani; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2012-04-28       Impact factor: 5.742

Review 2.  Contemporary Medical Management of Acute Severe Ulcerative Colitis.

Authors:  Kaitlin G Whaley; Michael J Rosen
Journal:  Inflamm Bowel Dis       Date:  2019-01-01       Impact factor: 5.325

Review 3.  Timing of surgery in Crohn's disease: a key issue in the management.

Authors:  Rafael Alós; Joaquín Hinojosa
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

4.  Corticosteroid therapy in ulcerative colitis: Clinical response and predictors.

Authors:  Jin Li; Fan Wang; Hong-Jie Zhang; Jian-Qiu Sheng; Wen-Feng Yan; Min-Xing Ma; Ru-Ying Fan; Fang Gu; Chuan-Feng Li; Da-Fan Chen; Ping Zheng; Yu-Pei Gu; Qian Cao; Hong Yang; Jia-Ming Qian; Pin-Jin Hu; Bing Xia
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

5.  The Writing Is on the Wall: The Utility of Mural Stratification for Risk Stratification of Hospitalized Patients with Severe Ulcerative Colitis.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Konstantinos C Thomopoulos
Journal:  Dig Dis Sci       Date:  2019-08       Impact factor: 3.199

Review 6.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 7.  Acute severe ulcerative colitis: from pathophysiology to clinical management.

Authors:  Pieter Hindryckx; Vipul Jairath; Geert D'Haens
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

8.  Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis.

Authors:  Hui-Min Wu; Juan Wei; Jin Li; Kai Wang; Lei Ye; Ying Qi; Bo-Si Yuan; Yu-Lin Yang; Li Zhao; Zhao Yang; Miao-Fang Yang; Jian-Feng Gong; Fang-Yu Wang
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

Review 9.  Severe ulcerative colitis: at what point should we define resistance to steroids?

Authors:  Maria Esteve; Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

10.  Gene expression changes associated with resistance to intravenous corticosteroid therapy in children with severe ulcerative colitis.

Authors:  Boyko Kabakchiev; Dan Turner; Jeffrey Hyams; David Mack; Neal Leleiko; Wallace Crandall; James Markowitz; Anthony R Otley; Wei Xu; Pingzhao Hu; Anne M Griffiths; Mark S Silverberg
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.